Concepedia

A phase l study of three different dosing schedules of the oral aurora kinase inhibitor MSC1992371A in patients with solid tumors

Monica Mita, Michael S. Gordon, N. Rejeb, Athos Gianella-Borradori, Virginie Jego, Alain C. Mita, J. Sarantopoulos, Kamalesh K. Sankhala, David S. Mendelson

Targeted Oncology · 2013 · 17 citations · 13 references

DOI

Concepts

References

13

New Guidelines to Evaluate the Response to Treatment in Solid Tumors

Patrick Therasse, Susan G. Arbuck, Elizabeth A. Eisenhauer et al. · JNCI Journal of the National Cancer Institute · 2000 · 15.7K citations

, , +12

Clinical evaluation of AZD1152, an i.v. inhibitor of Aurora B kinase, in patients with solid malignant tumors

David S. Boss, Petronella O. Witteveen, J. van der Sar et al. · Annals of Oncology · 2010 · 109 citations · Full text

, , +17

Phase I Pharmacokinetic and Pharmacodynamic Study of the Aurora Kinase Inhibitor Danusertib in Patients With Advanced or Metastatic Solid Tumors

Neeltje Steeghs, Ferry A.L.M. Eskens, Hans Gelderblom et al. · Journal of Clinical Oncology · 2009 · 105 citations

, , +15

A Phase I Dose-Escalation Study of Danusertib (PHA-739358) Administered as a 24-Hour Infusion with and without Granulocyte Colony-Stimulating Factor in a 14-Day Cycle in Patients with Advanced Solid Tumors

Roger B. Cohen, Suzanne F. Jones, Charu Aggarwal et al. · Clinical Cancer Research · 2009 · 93 citations · Full text

, , +16

Phase I dose escalation study of MK-0457, a novel Aurora kinase inhibitor, in adult patients with advanced solid tumors

Anne M. Traynor, Maureen R. Hewitt, Glenn Liu et al. · Cancer Chemotherapy and Pharmacology · 2010 · 86 citations · Full text

, , +14